Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development

References

• Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol. 2018;24(1):1–9.
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl. 1):4–13.
   PubMed Web of Science ®Google Scholar
• Kim KM, Kim J, Sinn DH, et al. Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment? Scand J Gastroenterol. 2018;53(6):727–733.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750.
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370.
   PubMed Web of Science ®Google Scholar
• Braillon A. Hepatocellular carcinoma. Lancet. 2012;380(9840):469.
   PubMedGoogle Scholar
• Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;156(5):387–389.
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim SY. Imaging modalities for hepatocellular carcinoma surveillance: expanding horizons beyond ultrasound. J Liver Cancer. 2020;20(2):99–105.
   Google Scholar
• Kim DH, Hong SB, Choi SH, et al. Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis. Gut. 2022;71(1):212–213.
   PubMedGoogle Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718.e1.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim B. Liver magnetic resonance imaging for hepatocellular carcinoma surveillance. J Liver Cancer. 2020;20(1):25–31.
   Google Scholar
• Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3(4):456–463.
   PubMed Web of Science ®Google Scholar
• Korean Liver Cancer Association, National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma. Korean J Radiol. 2019;20(7):1042–1113.
   PubMedGoogle Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–174.
   PubMed Web of Science ®Google Scholar
• Tanabe M, Kanki A, Wolfson T, et al. Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4 observations detected at CT and MR imaging. Radiology. 2016;281(1):129–139.
   PubMedGoogle Scholar
• Tang A, Bashir MR, Corwin MT, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286(1):29–48.
   PubMed Web of Science ®Google Scholar
• Agnello F, Albano D, Sparacia G, et al. Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up. Clin Imaging. 2020;68:169–174.
   PubMedGoogle Scholar
• Kim TK, Lee E, Jang HJ. Imaging findings of mimickers of hepatocellular carcinoma. Clin Mol Hepatol. 2015;21(4):326–343.
   PubMedGoogle Scholar
• Kim YK, Moon WS, Cho BH, et al. MRI findings of focal eosinophilic liver diseases. AJR Am J Roentgenol. 2005;184(5):1541–1548.
   PubMedGoogle Scholar
• Tang A, Singal AG, Mitchell DG, et al. Introduction to the liver imaging reporting and data system for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2019;17(7):1228–1238.
   PubMedGoogle Scholar
• van der Pol CB, Lim CS, Sirlin CB, et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy—a systematic review. Gastroenterology. 2019;156(4):976–986.
   PubMedGoogle Scholar
• Onyirioha K, Joshi S, Burkholder D, et al. Clinical outcomes of patients with suspicious (LI-RADS 4) liver observations. Clin Gastroenterol Hepatol. 2022.
   Google Scholar
• Arvind A, Joshi S, Zaki T, et al. Risk of hepatocellular carcinoma in patients with indeterminate (LI-RADS 3) liver observations. Clin Gastroenterol Hepatol. 2021.
   Google Scholar
• International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983–993.
   PubMed Web of Science ®Google Scholar
• Peng C, Kascakova S, Chiappini F, et al. Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature. J Transl Med. 2016;14:9.
   PubMed Web of Science ®Google Scholar
• Inchingolo R, Faletti R, Grazioli L, et al. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. World J Hepatol. 2018;10(7):462–473.
   PubMedGoogle Scholar
• Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer. 2006;106(3):636–647.
   PubMed Web of Science ®Google Scholar
• Sato T, Kondo F, Ebara M, et al. Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis: 28-year follow-up study. Hepatol Int. 2015;9(2):330–336.
   PubMedGoogle Scholar
• Korean Liver Cancer Association, National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019;13(3):227–299.
   PubMed Web of Science ®Google Scholar